Jingu finance news | Foundation medicine-B(02616) stock price rose in early trading, as of press time, up 4.17% to HKD 1.25 with a turnover of HKD 0.9285 million.
The company recently announced that the European Commission (EC) has approved the use of camrelizumab (trade name: Cejemly) in combination with platinum-based chemotherapy as a first-line treatment for adult patients with metastatic non-small cell lung cancer (NSCLC) without sensitive EGFR mutation, or ALK, ROS1, RET genomic tumor mutations. Camrelizumab became the first PD-L1 monoclonal antibody approved for first-line treatment of squamous and non-squamous NSCLC with combination chemotherapy in Europe, and foundation medicine is the first innovative biomedical enterprise to bring domestic PD-L1 monoclonal antibodies to the global market.